CMA Submission to the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities’ study of Bill C-3, An Act to amend the Criminal Code and the Canada Labour Code

https://policybase.cma.ca/link/policy14464

POLICY TYPE
Parliamentary submission

DATE
2021-12-15

TOPICS
Health care and patient safety
Ethics and medical professionalism
Vaccine acceptance
https://policybase.cma.ca/link/policy14450

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Return to school during COVID-19
https://policybase.cma.ca/link/policy14452

POLICY TYPE Policy document
DATE 2021-08-21
TOPICS Health care and patient safety
Population health, health equity, public health

Documents
Interchangeability of vaccines (vaccine mixing)

Policy document

2021-08-21

Health care and patient safety
Population health, health equity, public health

Interchangeability of vaccines (vaccine mixing)

Policy recommendation

1. The CMA recommends, for reasons mentioned above, the creation of a national expert panel on interchangeability of vaccines, including interchangeability of COVID-19 vaccines, to inform the best available evidence and expert panel on.

2. The CMA recommends that the government and administration of vaccines in the country be informed of the potential for vaccine interchangeability, both at and after manufacturing, in order to ensure the best available evidence and expert panel on.

Richard Silverman
Chair

Interchangeability of vaccines

1. Interchangeability of vaccines minimizes the likelihood of different vaccines used in the same population. This can be achieved through the use of different vaccines, developed by the same manufacturer, to achieve the same level of protection.

2. Interchangeability of vaccines can also be achieved by using different doses of the same vaccine, developed by the same manufacturer, to achieve the same level of protection.

3. Interchangeability of vaccines can also be achieved by using the same vaccine in different settings, developed by the same manufacturer, to achieve the same level of protection.

4. Interchangeability of vaccines can also be achieved by using the same vaccine in different populations, developed by the same manufacturer, to achieve the same level of protection.

5. Interchangeability of vaccines can also be achieved by using the same vaccine in different countries, developed by the same manufacturer, to achieve the same level of protection.

Interchangeability of SARS-CoV-2 vaccines

1. The CMA recommends that the government and administration of vaccines in the country be informed of the potential for vaccine interchangeability, both at and after manufacturing, in order to ensure the best available evidence and expert panel on.

2. The CMA recommends that the government and administration of vaccines in the country be informed of the potential for vaccine interchangeability, both at and after manufacturing, in order to ensure the best available evidence and expert panel on.

3. The CMA recommends that the government and administration of vaccines in the country be informed of the potential for vaccine interchangeability, both at and after manufacturing, in order to ensure the best available evidence and expert panel on.

4. The CMA recommends that the government and administration of vaccines in the country be informed of the potential for vaccine interchangeability, both at and after manufacturing, in order to ensure the best available evidence and expert panel on.
Firearms Control (Update 2021)
https://policybase.cma.ca/link/policy14401

POLICY TYPE
Policy document

DATE
2021-07-15

REPLACES
Firearms control (Update 2001)

TOPICS
Population health, health equity, public health
Health care and patient safety

Documents